Abstract: The present invention provides a vector comprising a nucleotide sequence encoding an anti-TNF antibody or a fragment thereof, wherein the nucleotide sequence encoding the anti-TNF antibody or a fragment thereof is operably linked to an inflammation-inducible promoter.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The present invention relates to an agent that increases expression of IRAK-M and/or activity of IRAK-M for use in a method of treatment or prophylaxis of macular degeneration in a subject. The agent may be one or more of a small molecule, a nucleic acid, a vector virion, a polypeptide, a nucleic acid system, a viral vector system, or a pharmaceutical composition.

Abstract: A system and method are described for evaluating mechanical properties of bone tissue. One example of the system of the present invention includes a first adjustable limb constraint and a second adjustable limb constraint collectively capable of immobilizing a patient's limb, such as the patient's arm, for vibration-based, in vivo mechanical bone property testing. One example of the method of the present invention includes providing a measurement stimulus and a data acquisition system for promoting accuracy and efficiency with respect to generation, organization, and evaluation of mechanical bone property data. One example of the method of the present invention includes providing system software capable of executing a CBMT algorithm for accurately determining mechanical properties of bone tissue.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Abstract: Provided are methods of enhancing and maintaining immune tolerance by modulation of CD200 or CD200R. Provided are antagonists thereof including antibodies.

Abstract: Provided are methods of enhancing and maintaining immune tolerance by modulation of CD200 or CD200R. Provided are antagonists thereof including antibodies.